与洛拉提尼布相关的不良事件管理的最新进展
Dehua Liao1, Jiwen Zhang1,2, Ting Yan1
1Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
OncoTargets and therapy
|September 11, 2023
概括
洛拉提尼布是一种第三代ALK抑制剂,在高级非小细胞肺癌 (NSCLC) 中表现出有效性. 本综述详细介绍了其安全性概况和对诸如高脂血症等不良事件的管理策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 洛拉提尼布是一种第三代ALK氨酸激酶抑制剂 (TKI),用于ALK阳性非小细胞肺癌 (NSCLC).
- 它显示出显著的全身和内活动,患者在早期的TKIs进展.
- 与其他ALK-TKI相比,洛拉提尼布具有独特的安全性.
研究的目的:
- 审查洛拉提尼布的安全性概况.
- 概述洛拉提尼布诱导的不良事件的管理策略.
- 为洛拉提尼布的临床应用提供实用指南.
主要方法:
- 对洛拉提尼布的安全性和有效性研究的文献评论.
- 分析报告的不良事件及其管理.
- 综合临床数据以提供实际指导.
主要成果:
- 洛拉提尼布在ALK突变的NSCLC中表现出显著的疗效,包括大脑转移.
- 关键不良事件包括高脂血症和中枢神经系统的影响.
- 这些事件通常可以通过剂量修改或药物治疗来控制,很少有永久性停药.
结论:
- 洛拉提尼布是晚期ALK阳性NSCLC的有效治疗选择.
- 了解和管理其独特的安全特性对于最佳的患者护理至关重要.
- 本综述为使用洛拉提尼布的临床医生提供了实际指导.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Pharmacovigilance
884
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
884
Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343
Adrenergic Antagonists: ɑ and β-Receptor Blockers
511
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
511
Drug Administration and Therapy Phases: Overview
518
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
518
Esophageal Varices-II: Clinical Features and Management
94
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
94


